These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33459161)

  • 1. Rituximab - The first twenty years.
    Leandro M; Isenberg DA
    Lupus; 2021 Mar; 30(3):371-377. PubMed ID: 33459161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
    Hui-Yuen JS; Nguyen SC; Askanase AD
    Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
    Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
    Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of systemic lupus erythematosus with epratuzumab.
    Traczewski P; Rudnicka L
    Br J Clin Pharmacol; 2011 Feb; 71(2):175-82. PubMed ID: 21219397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic therapies for systemic lupus erythematosus: where are we now?
    Murphy G; Isenberg DA
    Curr Opin Rheumatol; 2020 Nov; 32(6):597-608. PubMed ID: 32890026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Connective tissue diseases: The conundrum of B cell depletion in SLE.
    Sanz I
    Nat Rev Rheumatol; 2009 Jun; 5(6):304-5. PubMed ID: 19491910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anifrolumab (Saphnelo) for systemic lupus erythematosus.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):146-147. PubMed ID: 34550961
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.
    Zhang H; Chambers W; Sciascia S; Cuadrado MJ
    Expert Rev Clin Pharmacol; 2016; 9(5):681-94. PubMed ID: 26907827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus.
    Carreira PL; Isenberg DA
    Rheumatology (Oxford); 2019 Mar; 58(3):382-387. PubMed ID: 29660084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 19. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined rituximab and belimumab to treat recalcitrant epidermolysis bullosa aquisita associated with systemic lupus erythematosus.
    Tull TJ; Benton EC; Semkova K; Watson NA; Mee JB; Lopez B; Setterfield J; Carey B; Ahmad S; Robbie SJ; Groves RW; Sanna G; D'Cruz DP
    Br J Dermatol; 2024 Jun; 191(1):138-140. PubMed ID: 38561894
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.